Uncategorized
Glaukos Provides Update on COVID-19 Impact and Preliminary Net Sales Range for the First Quarter of 2020
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today provided an update on the impact of the COVID-19 pandemic on the company and announced a preliminary net sales range for its first quarter of 2020. Preliminary and Unaudited First Quarter 2020 Net Sales and COVID-19 Response Preliminary and unaudited net sales f